|Bid||0.00 x 1300|
|Ask||38.00 x 900|
|Day's Range||35.03 - 37.16|
|52 Week Range||16.69 - 41.57|
|Beta (3Y Monthly)||2.18|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 30, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||57.36|
Alnylam (ALNY) completes enrollment in its ILLUMINATE-A phase III study on lumasiran for the treatment of adults and children with primary hyperoxaluria type 1.
Medicines Co NASDAQ/NGS:MDCOView full report here! Summary * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for MDCO with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting MDCO. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold MDCO had net inflows of $2.46 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]
Alnylam (ALNY) completes the rolling NDA submission to the FDA for givosiran, which is being evaluated for the treatment of acute hepatic porphyria.
The Medicines Company (NASDAQ: MDCO ) shares traded higher by 2.5 percent on Tuesday and are now up 7.5 percent overall in the past week. At this point, Medicines Company traders are likely considering ...
Investors need to pay close attention to Medicines Company (MDCO) stock based on the movements in the options market lately.
Alnylam (ALNY) initiates phase I study on ALN-AGT, an investigational RNAi therapeutic targeting angiotensinogen for the treatment of hypertension in high unmet need populations.
Conventional wisdom says that insiders and 10 percent owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. Zillow Group Inc (NASDAQ: Z) had a director return for more notable indirect share purchases this past week. Zillow's new business in buying and selling homes has helped boost its revenue.
A combined analysis (N=279) from the Phase 2 ORION-1 and Phase 1 ORION-7 trials, presented during an e-poster session, demonstrated that patients across a range of renal function levels achieved consistent reductions in low-density lipoprotein cholesterol (LDL-C) with no dose adjustment necessary for patients with renal impairment. Results from the Phase 2 ORION-2 pilot study, presented as a late-breaking abstract, showed that inclisiran provided durable reductions in LDL-C levels up to day 180 in patients with homozygous familial hypercholesterolemia (HoFH), a genetic disorder characterized by very high levels of LDL-C and early onset of cardiovascular disease, without the need to increase the dose of inclisiran.
Medicines Co. (MDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medicines Company announced interim results Saturday from the ongoing Phase 2 ORION-3 study that is evaluating the efficacy, safety and tolerability of inclisiran 300 mg in patients with atherosclerotic cardiovascular disease and elevated LDL cholesterol. The results show a consistent lowering of LDL cholesterol by more than 50 percent, with an overall follow-up of up to three years. The results were presented as a late-breaking presentation at the National Lipid Association Scientific Sessions in Miami.
NEW YORK, May 20, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of The Medicines Company (MDCO). You may also contact Robert H. Lefkowitz, Esq. Purcell Julie & Lefkowitz LLP is a law firm exclusively committed to representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty and other types of corporate misconduct.
The Medicines Company (MDCO) today announced interim results from the ongoing ORION-3 open-label extension study (Group 1, n=290) which showed that twice-a-year dosing with inclisiran sodium 300 mg resulted in consistent lowering of low density lipoprotein cholesterol (LDL-C) by more than 50 percent with overall follow-up of up to three years. Inclisiran was well tolerated, and no material safety issues were observed in the study.
Anyone researching The Medicines Company (NASDAQ:MDCO) might want to consider the historical volatility of the share...
Biotech stocks saw a reversal in sentiment as the week saw an earnings deluge from small-, micro- and nano-cap biotechs and some M&A activity . Here are some key catalysts for the unfolding week that should ...
The Medicines Company (MDCO) will host a conference call and webcast for investors on Saturday, May 18, 2019, at 5:30 p.m. EDT. During the call, the Company’s management and clinical trial investigators will review interim results on the long-term safety and efficacy data of inclisiran from the ongoing ORION-3 study.
The Medicines Company announced that it will participate in the Bank of America Merrill Lynch 2019 Healthcare Conference on Tuesday, May 14, 2019, in Las Vegas. The Company is scheduled to present at 8:00 a.m.
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]